Dossier
Poolbeg Pharma
Coverage of Poolbeg Pharma in the Nexus archive.
- London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’
London-based startup Poolbeg Pharma is trialing POLB 001 at six NHS hospitals to prevent cytokine release syndrome in cancer patients undergoing immunotherapy. The company is also developing a GLP-1 weight loss pill.
- SMALL CAP IDEA: Poolbeg Pharma and the oral drug that could unlock cancer immunotherapy's biggest problem
Poolbeg Pharma is developing an oral drug aimed at addressing a major challenge in cancer immunotherapy. The treatment could potentially enhance the effectiveness of existing immunotherapy approaches.